VCRO’s professional team assisted in preparing the submission to the US FDA for a clinical trial of client’s TCR-T cell therapy product targeting HPV-related solid tumors. In early July 2024, they received FDA approval to initiate Phase I/II clinical trials, thereby successfully enabling our client to conduct both phases within a single trial design.
With extensive experience in the field of cell therapy spanning over many years since 2008, VCRO has accumulated a portfolio of more than 47 projects. Our wealth of experience ensures clients benefit from comprehensive clinical strategy planning and smooth execution processes.
